摘要
目的研究黄芩苷对呼吸道合胞病毒(RSV)复制、转录及融合效应的影响,探讨临床验方金欣口服液的药效物质基础。方法构建RSV感染的Hep-2细胞模型,黄芩苷干预后采用体外转录法、实时荧光定量PCR法及免疫荧光显微法分别检测黄芩苷对RSV的RNA聚合酶活性、核酸复制及RSV介导的细胞融合作用。结果在50μmol/L的最大无毒浓度下,黄芩苷对RSV的RNA依赖的RNA聚合酶活性、核酸复制、F融合蛋白表达及其介导的细胞融合效应无显著作用。结论黄芩苷不能抑制RSV的转录、复制及融合。金欣口服液治疗RSV肺炎的主要药效成分可能非黄芩苷而为其他含量较低成分或黄芩苷代谢产物,有待进一步确定。
AIM To study whether the effects of baicalin （main component of Jinxin Oral Liquid） on tran- scription and duplication of respiratory syncytial virus （RSV） as well as cell fusion induced by RSV will occur. METHODS RSV-infected Hep-2 cell model was constructed and experimental methods, such as transcription in vitro, real time quantitive PCR and immunofluorescence microscopy were used respectively to detect the RNA poly- merase activity, nucleic acid duplication and cell fusion induced by RSV. RESULTS There was no significant effect of baicalin at the maximum nontoxic concentration of 50 I.Lmol/L on the observed index above. CONCLU- SION Baicalin can not inhibit the transcription and duplication of RSV as well as cell fusion induced by RSV. A- mong the curative effects of Jinxin Oral Liquid for RSV pneumonia, whether the antiviral activity of other low-content components, such as wogonin or metabolic products of baicalin remains to be determined.
出处
《中成药》
CAS
CSCD
北大核心
2011年第12期2055-2058,共4页
Chinese Traditional Patent Medicine
基金
国家自然科学基金项目(81072840)
江苏省中医药局科技项目(LB09021)
南京中医药大学基础研究项目(10XJC04)
